Sponsors Request More Bioequivalence Details in Guidance

International Pharmaceutical Regulatory Monitor
A A
Sponsors would like to see clearer recommendations for non-inferiority assessments, demonstrating bioequivalence and targets for statistical analysis, before the European Medicines Agency adopts an international guideline on large clinical trials that span multiple regions.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor